Sharon E Jacob1, Mehdi Nassiri, Francisco A Kerdel, Vladimir Vincek. 1. Department of Dermatology and Cutaneous Surgery, University of Miami/ Jackson Memorial Medical Center, Holtz Center, Room 2042, 1611 NW 12 Avenue, Miami, FL 33136, USA.
Abstract
BACKGROUND: Psoriatic plaques have been shown to contain increased levels of proinflammatory cytokines. Serum levels of interleukin (IL)-6, IL-7, IL-8, and interferon (IFN)-gamma have been reported elevated in psoriatic patients. AIM: To evaluate serum cytokine profiles in psoriasis patients by improved enzyme-linked immunosorbent assay (ELISA) technique and to correlate these levels with disease severity. METHODS: We analyzed single serum samples from 10 patients with active untreated psoriasis, two patients with active treated psoriasis, and five healthy volunteers for major T helper type 1 and T helper type 2 cytokines using the LINCOplex ELISA multi-analyte detection system that permits simultaneous detection of multiple cytokines from a single sample. The disease severity, including erythema, induration, scale, and surface area, was assessed. RESULTS: IFN-gamma was markedly elevated in all sera from psoriasis patients, 33.8 +/- 1.3 pg/ml (mean +/- standard error) versus 8 +/- 1.5 pg/ml for normal controls (p < 0.01), and positively correlated with all indices of disease severity (Spearman r > 0.6). IL-8 was also increased in psoriasis patients (24.4 +/- 1.8 pg/ml) versus normal controls (3.6 +/- 1.2 pg/ml) (p < 0.05) and positively correlated with the degree of erythema (Spearman r > 0.6). Mean IL-12 levels were decreased in sera from psoriasis patients (8.5 +/- 1.2 pg/ml) compared with normal controls (42.2 +/- 5.3 pg/ml) (p < 0.01). Also, serum IL-10 levels were below detection levels in psoriatics compared with controls (6.4 +/- 1.3 pg/ml). CONCLUSIONS: This new ELISA system allowed rapid and reliable detection of numerous cytokines in single serum samples from patients with psoriasis. We observed that IFN-gamma and IL-8 cytokines were elevated in psoriatics and correlated with parameters of disease severity while IL-10 and IL-12 were decreased.
BACKGROUND:Psoriatic plaques have been shown to contain increased levels of proinflammatory cytokines. Serum levels of interleukin (IL)-6, IL-7, IL-8, and interferon (IFN)-gamma have been reported elevated in psoriaticpatients. AIM: To evaluate serum cytokine profiles in psoriasispatients by improved enzyme-linked immunosorbent assay (ELISA) technique and to correlate these levels with disease severity. METHODS: We analyzed single serum samples from 10 patients with active untreated psoriasis, two patients with active treated psoriasis, and five healthy volunteers for major T helper type 1 and T helper type 2 cytokines using the LINCOplex ELISA multi-analyte detection system that permits simultaneous detection of multiple cytokines from a single sample. The disease severity, including erythema, induration, scale, and surface area, was assessed. RESULTS:IFN-gamma was markedly elevated in all sera from psoriasispatients, 33.8 +/- 1.3 pg/ml (mean +/- standard error) versus 8 +/- 1.5 pg/ml for normal controls (p < 0.01), and positively correlated with all indices of disease severity (Spearman r > 0.6). IL-8 was also increased in psoriasispatients (24.4 +/- 1.8 pg/ml) versus normal controls (3.6 +/- 1.2 pg/ml) (p < 0.05) and positively correlated with the degree of erythema (Spearman r > 0.6). Mean IL-12 levels were decreased in sera from psoriasispatients (8.5 +/- 1.2 pg/ml) compared with normal controls (42.2 +/- 5.3 pg/ml) (p < 0.01). Also, serum IL-10 levels were below detection levels in psoriatics compared with controls (6.4 +/- 1.3 pg/ml). CONCLUSIONS: This new ELISA system allowed rapid and reliable detection of numerous cytokines in single serum samples from patients with psoriasis. We observed that IFN-gamma and IL-8 cytokines were elevated in psoriatics and correlated with parameters of disease severity while IL-10 and IL-12 were decreased.
Authors: Allan Hildesheim; Rick L Ryan; Elizabeth Rinehart; Sonali Nayak; Dora Wallace; Philip E Castle; Shelley Niwa; William Kopp Journal: Cancer Epidemiol Biomarkers Prev Date: 2002-11 Impact factor: 4.254
Authors: T Shimizu; J Nishihira; Y Mizue; H Nakamura; R Abe; H Watanabe; A Ohkawara; H Shimizu Journal: J Invest Dermatol Date: 2001-06 Impact factor: 8.551
Authors: I B McInnes; G G Illei; C L Danning; C H Yarboro; M Crane; T Kuroiwa; R Schlimgen; E Lee; B Foster; D Flemming; C Prussin; T A Fleisher; D T Boumpas Journal: J Immunol Date: 2001-10-01 Impact factor: 5.422
Authors: Jane Zochling; Martin H J Bohl-Bühler; Xenofon Baraliakos; Ernst Feldtkeller; Jürgen Braun Journal: Clin Rheumatol Date: 2005-12-23 Impact factor: 2.980
Authors: Jacqueline M Benson; David Peritt; Bernard J Scallon; George A Heavner; David J Shealy; Jill M Giles-Komar; Mary Ann Mascelli Journal: MAbs Date: 2011-11-01 Impact factor: 5.857
Authors: Lizhi Hu; Theodora M Mauro; Erle Dang; George Man; Jing Zhang; Dale Lee; Gang Wang; Kenneth R Feingold; Peter M Elias; Mao-Qiang Man Journal: J Invest Dermatol Date: 2017-01-20 Impact factor: 8.551
Authors: D Fleissner; K Loser; W Hansen; J Dissemond; A Körber; S Beissert; J Buer; A M Westendorf Journal: Eur J Microbiol Immunol (Bp) Date: 2011-09-09